Genentech, Inc.

Trellis Bioscience, Inc.

23andme, Inc.

Genetech, Inc.

Krista Maureen McCutcheon

Lawrence M Kauvar

William Usinger

Minha Park

Stote Ellsworth

Austin L Gurney

Camellia W Adams

Jane Louise Grogan

Ying-Ping Jiang

Bo Chen

Orit Foord

Fen Zhang

Gizette Sperinde

Paul Polakis

Robert F Kelley

Chingwei Vivian Lee

Ron Firestein

Yu Chen

Shouhua Xiao

Jyoti Asundi

Germaine Fuh-Kelly

Yao-ming Huang

Louise Scharf

Samuel Nalle

Tina Thai

Zuoan Yi

Valentine Yeung

Augusta Eleanor Broughton

Navneet Singh

An Song

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.

Anti-CD96 antibodies and methods of use thereof

Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.

Antibodies useful in passive influenza immunization

Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.

Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

High affinity human antibodies to human cytomegalovirus (CMV) gB protein

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Compositions and methods for the diagnosis and treatment of tumor

High affinity human antibodies to human cytomegalovirus (CMV) GB protein

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

The invention provides various antibodies that bind to lymphotoxin-&#x3b1;, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.

Antibodies to lymphotoxin-alpha

Antibodies to lymphotoxin-&#x3b1;

The present application describes a method for pretreating a biological sample from an autoimmune disease subject in order to avoid interference, especially where the sample is to be subjected to a cell-based biological activity assay, such as a neutralizing antibody assay.

Pretreatment of a biological sample from an autoimmune disease subject

Growing community of inventors

Burlingame, CA, United States of America

Krista Maureen McCutcheon